Is Truvada (emtricitabine and tenofovir disoproxil fumarate) considered Pre-Exposure Prophylaxis (PrEP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Truvada as Pre-Exposure Prophylaxis (PrEP)

Yes, Truvada (emtricitabine and tenofovir disoproxil fumarate) is definitively considered a form of pre-exposure prophylaxis (PrEP) for HIV prevention and is the original FDA-approved medication for this purpose. 1, 2

What is Truvada?

  • Truvada is a fixed-dose combination tablet containing 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF) 1
  • It was the first medication approved for use as PrEP for HIV prevention 2
  • Truvada is marketed by Gilead Sciences and is now also available as a generic medication 1

Truvada's Role in PrEP

  • Truvada is recommended as a daily oral PrEP regimen for all populations at risk of HIV infection through sexual exposure or injection drug use 1, 3
  • It has demonstrated high efficacy in preventing HIV acquisition when taken as prescribed 1, 4
  • For MSM, Truvada can be used either as daily PrEP or as on-demand (2-1-1) dosing 1, 4
  • For women and people who inject drugs, only daily dosing of Truvada is recommended 5, 4

Dosing Considerations

  • Daily dosing: One tablet of Truvada taken once daily is the standard regimen for all populations 1, 3
  • On-demand (2-1-1) dosing (for MSM only):
    • 2 tablets taken 2-24 hours before sex
    • 1 tablet 24 hours after the first dose
    • 1 tablet 24 hours after the second dose 1, 4
  • Daily dosing is especially important for women as tenofovir concentrates at 10-fold lower levels in vaginal tissue compared to rectal tissue 5, 6

Effectiveness

  • Truvada has been shown to reduce HIV acquisition by up to 44% in the general population and by up to 92% when adherence is high 1
  • Even against FTC-resistant HIV strains, Truvada maintains prophylactic efficacy due to the presence of tenofovir 7
  • Protection begins after approximately 7 days of daily use for vaginal exposure and potentially sooner for rectal exposure 1, 3

Monitoring Requirements

  • HIV testing must be performed before initiating Truvada as PrEP 1, 4
  • Regular follow-up visits (typically every 3 months) are required for:
    • HIV testing
    • STI screening
    • Renal function assessment
    • Adherence counseling 1, 4
  • PrEP prescriptions should not exceed 90 days without interval HIV testing 1, 4

Important Considerations

  • Truvada does not protect against other sexually transmitted infections 5, 4
  • Adherence is critical for effectiveness 2
  • Truvada is safe for use during pregnancy and breastfeeding 3
  • Caution is needed in patients with renal impairment (creatinine clearance <60 mL/min) 4
  • For patients with renal concerns or bone health issues, tenofovir alafenamide/emtricitabine (Descovy) may be an alternative for MSM, but not for those at risk through vaginal sex 4, 8

Truvada remains a cornerstone of HIV prevention strategies worldwide, with extensive evidence supporting its safety and efficacy when used as directed.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pre-Exposure Prophylaxis for HIV Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

HIV Pre-Exposure Prophylaxis Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guidelines for HIV Pre-Exposure Prophylaxis in Females

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.